These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


66 related items for PubMed ID: 9214205

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L, Manieri C, Paradiso Galatioto G, Vicentini C.
    Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
    [Abstract] [Full Text] [Related]

  • 4. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O, Lehtonen T, Talja M, Lundstedt S, Tiitinen J, Taari K.
    Ann Chir Gynaecol; 1999; 88(4):299-303. PubMed ID: 10661828
    [Abstract] [Full Text] [Related]

  • 5. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, Kontturi M, Lehtonen T.
    Tidsskr Nor Laegeforen; 1996 Nov 10; 116(27):3226-30. PubMed ID: 9011975
    [Abstract] [Full Text] [Related]

  • 7. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar 10; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA.
    Bangladesh Med Res Counc Bull; 2005 Aug 10; 31(2):54-61. PubMed ID: 16967810
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P.
    Arch Esp Urol; 1994 Nov 10; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
    Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM.
    CMAJ; 1996 Nov 01; 155(9):1251-9. PubMed ID: 8911291
    [Abstract] [Full Text] [Related]

  • 11. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr 01; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 12. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 01; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 13. [Finasteride in the treatment of benign prostatic hypertrophy].
    Ekman P.
    J Urol (Paris); 1993 May 01; 99(6):299-302. PubMed ID: 7516372
    [Abstract] [Full Text] [Related]

  • 14. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 15. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
    Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J, Pless Study Group.
    J Urol; 2002 May 15; 167(5):2105-8. PubMed ID: 11956450
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA, MICTUS Study Group.
    Prostate Cancer Prostatic Dis; 2003 May 15; 6(4):315-23. PubMed ID: 14663474
    [Abstract] [Full Text] [Related]

  • 17. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN, Al'-Shukri SKh, Kornienko VI, Kuz'min IV.
    Urol Nefrol (Mosk); 1998 May 15; (4):37-9. PubMed ID: 9727320
    [Abstract] [Full Text] [Related]

  • 18. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
    Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group.
    J Urol; 2001 Oct 15; 166(4):1358-63. PubMed ID: 11547074
    [Abstract] [Full Text] [Related]

  • 19. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
    de la Taille A.
    Prog Urol; 2008 Apr 15; 18 Suppl 3():S53-7. PubMed ID: 18455085
    [Abstract] [Full Text] [Related]

  • 20. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.